161,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
81 °P sammeln
  • Broschiertes Buch

A. Michael Lincoff takes advantage of critically important new knowledge arising from recent clinical trials to update and expand his acclaimed Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. This substantially enhanced Second Edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes, on outcomes with chronic oral GPIIb/IIIa blockade following acute coronary syndromes, and on fibrinolytic therapy during acute myocardial infarctions. Additional enhancements include revised findings from the latest trials of GPIIb/IIIa inhibition during…mehr

Produktbeschreibung
A. Michael Lincoff takes advantage of critically important new knowledge arising from recent clinical trials to update and expand his acclaimed Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. This substantially enhanced Second Edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes, on outcomes with chronic oral GPIIb/IIIa blockade following acute coronary syndromes, and on fibrinolytic therapy during acute myocardial infarctions. Additional enhancements include revised findings from the latest trials of GPIIb/IIIa inhibition during percutaneous coronary intervention, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. The book also explains the scientific basis of this therapy, evaluates its benefits and risks for patients, and summarizes detailed data from its various clinical trials.
Comprehensive and definitive, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, Second Edition offers physicians, cardiologists, emergency room doctors, and basic scientists a complete and authoritative review of the state-of-the-art in glycoprotein IIb/IIIa receptor inhibitor use today.
Rezensionen
"...provides the reader with extensive and profound information about this new class, based on data from completed and ongoing trials...can be recommended not only to cardiologists but to all clinicians and researchers interested in this field." -Intensive Care Medicine